مکتبة رقمیه للعلوم الطبيه
Your cart is empty.
  • Cart
  • Lists
    Your lists Log in to create your own lists
  • Log in to your account
  • Your cookies
  • Search history
  • Advanced search
  • Authority search
  • Tag cloud
  • Library

Log in to your account

  1. Home
  2. Details for: Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Normal view MARC view ISBD view

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. [electronic resource]

By:
  • Schwab, C L
Contributor(s):
  • Bellone, S
  • English, D P
  • Roque, D M
  • Lopez, S
  • Cocco, E
  • Nicoletti, R
  • Bortolomai, I
  • Bonazzoli, E
  • Ratner, E
  • Silasi, D-A
  • Azodi, M
  • Schwartz, P E
  • Rutherford, T J
  • Santin, A D
Producer: 20150109Description: 1750-6 p. digitalISSN:
  • 1532-1827
Subject(s):
  • Adult
  • Afatinib
  • Aged
  • Aged, 80 and over
  • Animals
  • Apoptosis -- drug effects
  • Cell Cycle -- drug effects
  • Cell Proliferation -- drug effects
  • Cystadenocarcinoma, Serous -- drug therapy
  • Endometrial Neoplasms -- drug therapy
  • Female
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • In Vitro Techniques
  • Mice
  • Mice, SCID
  • Middle Aged
  • Phosphorylation -- drug effects
  • Quinazolines -- pharmacology
  • Receptor, ErbB-2 -- genetics
  • Signal Transduction -- drug effects
  • Tumor Cells, Cultured
  • Uterine Neoplasms -- drug therapy
  • Xenograft Model Antitumor Assays
Online resources:
  • Available from publisher's website
In: British journal of cancer vol. 111
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Cancel rating. Average rating: 0.0 (0 votes)
  • Holdings ( 0 )
  • Title notes ( 1 )
  • Comments ( 0 )
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

Log in to your account to post a comment.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

APA

Schwab C. L., Bellone S., English D. P., Roque D. M., Lopez S., Cocco E., Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D., Azodi M., Schwartz P. E., Rutherford T. J. & Santin A. D. (20150109). Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

Chicago

Schwab C L, Bellone S, English D P, Roque D M, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D-A, Azodi M, Schwartz P E, Rutherford T J and Santin A D. 20150109. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

Harvard

Schwab C. L., Bellone S., English D. P., Roque D. M., Lopez S., Cocco E., Nicoletti R., Bortolomai I., Bonazzoli E., Ratner E., Silasi D., Azodi M., Schwartz P. E., Rutherford T. J. and Santin A. D. (20150109). Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer.

MLA

Schwab C L, Bellone S, English D P, Roque D M, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi D-A, Azodi M, Schwartz P E, Rutherford T J and Santin A D. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. : British journal of cancer. 20150109.

  • Print
  • Cite
  • Add to your cart (remove)
  • Save record
    BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
  • More searches
    Search for this title in:
    Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Visit web site